Literature DB >> 1899689

Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system.

L R Wing1, G M Hawksworth, B Bennett, N A Booth.   

Abstract

The role of physiologic inhibitors of tissue-type plasminogen activator (t-PA) in its clearance has not yet been defined. In this study, the clearance of t-PA, plasminogen activator inhibitor 1 (PAI-1), and t-PA-PAI-1 complex was determined in an isolated perfused rat liver system. The clearance of t-PA-PAI-1 complex was twice as fast as that of t-PA, whereas PAI-1 was cleared slowly. The half-lives for t-PA, determined by a two-compartmental pharmacokinetic model, were: alpha, 20.1 minutes, and beta, 120.0 minutes. The corresponding values for t-PA-PAI-1 complex were: alpha, 9.7 minutes, and beta, about 7 hours. The model microconstants were computed for t-PA and t-PA-PAI-1 complex and the marked difference between the "on" microconstants k12 for t-PA (0.026 +/- 0.001 min-1) and t-PA-PAI-1 complex (0.090 +/- 0.025 min-1) suggests that the effect on binding to liver cells is the most important factor in the faster clearance of t-PA-PAI-1 complex when compared with t-PA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899689

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  9 in total

1.  Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases.

Authors:  P Fitch; B Bennett; N A Booth; A Croll; S W Ewen
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

2.  Elevation of Plasminogen Activator Inhibitor-1 promotes differentiation of Cancer Stem-like Cell state by Hepatitis C Virus infection.

Authors:  Da-Eun Nam; Angelina Angelucci; Dahsom Choi; Arnold Leigh; Hae Chang Seong; Young S Hahn
Journal:  J Virol       Date:  2021-02-24       Impact factor: 5.103

3.  Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.

Authors:  K Leiper; A Croll; N A Booth; N R Moore; T Sinclair; B Bennett
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

4.  Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.

Authors:  K Orth; E L Madison; M J Gething; J F Sambrook; J Herz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

5.  Characterization of the binding of plasminogen activators to plasma membranes from human liver.

Authors:  G Nguyen; S J Self; C Camani; E K Kruithof
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

6.  Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions.

Authors:  J Kuiper; A Van't Hof; M Otter; E A Biessen; D C Rijken; T J van Berkel
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

7.  Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus.

Authors:  Helena Atroch Machado; Marcelo Vieira; Maria Rosaria Cunha; Marcia Regina Soares Correia; Rosa Tsunechiro Fukui; Rosa Ferreira dos Santos; Dalva Marreiro Rocha; Bernardo Leo Wajchenberg; Silvia G Lage; Maria Elizabeth Rossi da Silva
Journal:  Clinics (Sao Paulo)       Date:  2012-07       Impact factor: 2.365

8.  Increased PAI-1 plasma levels and risk of death from dengue: no association with the 4G/5G promoter polymorphism.

Authors:  A T A Mairuhu; T E Setiati; P Koraka; C E Hack; A Leyte; S M H Faradz; H ten Cate; D P M Brandjes; A D M E Osterhaus; P H Reitsma; E C M van Gorp
Journal:  Thromb J       Date:  2005-11-07

9.  Level of receptor-associated protein moderates cellular susceptibility to pseudomonas exotoxin A.

Authors:  D Mucci; J Forristal; D Strickland; R Morris; D Fitzgerald; C B Saelinger
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.609

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.